Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease.

中文翻译：

---

肝病和 COVID-19：从病理生理学到治疗策略

在 SARS-CoV-2 爆发和 COVID-19 大流行的后续发展之后，肺、肾、肝、心脏和大脑等器官已被确定为优先器官。肝病被认为是 COVID-19 大流行导致高死亡率的危险因素。此外，相当一部分COVID-19患者，尤其是那些临床症状严重的患者，已经证实存在肝损伤。此外，抗病毒药物、肝移植后的免疫抑制药物、既往肝病和肝硬化等慢性肝病也与 SARS-CoV-2 引起的肝损伤有关。因此，已经采取了一些预防措施来预防、监测病毒，并避免免疫功能低下和易感人群，例如肝肾移植受者、免于感染 SARS-CoV-2，从而避免死亡率增加。本综述的目的是检查 SARS-CoV-2 感染造成的损害以及大流行期间使用的药物对死亡率范围的影响，以及因此对肝病患者采取预防措施的可能性。